Skip to content

Neuropsychological Evaluation for Early Diagnosis of PSP

The Role of the Neuropsychological Evaluation for Early Diagnosis of Progressive Supranuclear Palsy

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03478124
Enrollment
112
Registered
2018-03-27
Start date
2016-01-01
Completion date
2018-03-02
Last updated
2018-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive Impairment, Progressive Supranuclear Palsy

Brief summary

The aim of this study is to better understand the nature of the cognitive decline in Progressive Supranuclear Palsy, the time of its development and the relation with the other cardinal features of the disease.

Detailed description

Progressive Supranuclear Palsy (PSP) is a neurodegenerative disease characterized by vertical supranuclear gaze palsy, early balance dysfunction and falls. Tau-protein aggregation, mainly in the brainstem, is the disease hallmark. Because of the similarities with Parkinson's disease (PD), the diagnosis is made approximately 4 years after the symptoms onset. Cognitive deficits are a leading feature of PSP and they actually represent one of the four functional core domains in the revised diagnostic criteria. The aim of this study is to better understand the nature of this cognitive decline, the time of its development and the relation with the other cardinal features of the disease.

Interventions

An extensive battery of neuropsychological and motor tests was assessed: MMSE, FAB, MoCA, WCST, Stroop Test, TMT-A and B, Verbal fluency Test, ROCF copy and delayed recall, RAVLT, 6MWT, TUG, BBS.

Sponsors

Ospedale Generale Di Zona Moriggia-Pelascini
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Inclusion criteria

* Patients fulfilling the criteria for idiopathic PD * Patients fulfilling the criteria for PSP

Exclusion criteria

* Any other neurodegenerative disorders or medical conditions different from PD / PSP

Design outcomes

Primary

MeasureTime frameDescription
RAVLT1 yearRey Auditory Verbal Learning Test
TMT-A and B1 yearTrail Making Test Parts A & B
VFT1 yearVerbal fluency Test
ROCF copy and delayed recall1 yearRey-Osterrieth complex figure test copy and delayed recall
MMSE1 yearMini-Mental State Examination
FAB1 yearFrontal Assessment Battery
MoCA1 yearMontreal Cognitive Assessment
WCST1 yearWisconsin Card Sorting Test
ST1 yearStroop Test

Secondary

MeasureTime frameDescription
TUG1 yearTimed Up and Go Test
BBS1 yearBerg Balance Scale
6MWT1 year6 Minute Walk Test

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026